Your browser doesn't support javascript.
loading
Unraveling the Rare Entity of KIT D816V-Negative Systemic Mastocytosis.
Alyamany, Ruah; Albachir, Chams Alkhalaf; Alsaleh, Sarah; Hamad, Alaa; Abdulwali, Sameeha Kaiser; Alotaibi, Ahmad S; Ahmed, Syed Osman; Alfayez, Mansour.
Affiliation
  • Alyamany R; Department of Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
  • Albachir CA; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Alsaleh S; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Hamad A; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Abdulwali SK; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Alotaibi AS; Department of Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
  • Ahmed SO; Department of Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
  • Alfayez M; Department of Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
J Hematol ; 13(3): 128-136, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38993735
ABSTRACT
Systemic mastocytosis (SM) is a rare type of myeloproliferative neoplasm characterized by abnormal proliferation and infiltration of different tissue by clonal mast cells. The uncontrolled proliferation and activation of mast cells trigger the release of vasoactive and inflammatory mediators, resulting in a cascade of systemic symptoms. Around 95% of SM arise from a gain-of-function mutation at the KIT gene, specifically at codon 816, which highlights its essential role in SM and makes it an attractive target for therapy. Although KIT-negative SM is exceptionally rare, the increased number of cases documented in the literature makes it an intriguing dimension of this disorder. The reported clinical manifestations of KIT-negative SM are widely variable, but many are similar to KIT-positive SM. KIT-targeted therapeutic options have been a game-changer in KIT-positive SM, however their role in KIT-negative SM remains controversial. This report aimed to further understand KIT-negative SM by presenting two cases of KIT-negative SM, one of which was responsive to KIT-targeted therapy, and analyzing reported cases in the existing literature.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Hematol Year: 2024 Document type: Article Affiliation country: Arabia Saudita Country of publication: Canadá

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Hematol Year: 2024 Document type: Article Affiliation country: Arabia Saudita Country of publication: Canadá